The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review

Oliver Pearson, Nora Uglik-Marucha, Kamilla W. Miskowiak, Scott A. Cairney, Ivana Rosenzweig, Allan H. Young, Paul R.A. Stokes
doi: https://doi.org/10.1101/2021.08.12.21261470

Abstract

Background Cognitive impairment experienced by people with bipolar disorders (BD) or major depressive disorder (MDD) is associated with impaired psychosocial function and poorer quality of life. Sleep disturbance is another core symptom of mood disorders which may be associated with, and perhaps worsen, cognitive impairments. The aim of this systematic review was to critically assess the relationship between sleep disturbance and cognitive impairment in mood disorders.

Methods In this systematic review, relevant studies which examined sleep disturbance and cognitive function in people with mood disorders were identified using electronic database searches of PsychINFO, MEDLINE, Embase and Web of Science.

Findings Fourteen studies were included; eight investigated people with BD, five investigated people with MDD, and one included both people with MDD and people with BD. One study was an intervention for sleep disturbance and the remaining thirteen studies used either a longitudinal or cross-sectional observational design. Ten studies reported a significant association between subjectively measured sleep disturbance and cognitive impairment in people with MDD or BD after adjusting for demographic and clinical covariates, whereas no such association was found in healthy participants. Two studies reported a significant association between objectively measured sleep abnormalities and cognitive impairment in mood disorders. One study of cognitive behavioural therapy for insomnia modified for BD (CBTI-BD) found an association between improvements in sleep and cognitive performance in BD.

Interpretation There is preliminary evidence to suggest a significant association between sleep disturbance and cognitive impairment in mood disorders. These findings suggest that identifying and treating sleep disturbance may be important when addressing cognitive impairment in MDD and BD.

Funding none.

Introduction

Cognitive impairment in people with bipolar disorders (BD) or major depressive disorder (MDD) is associated with reduced functional capacity,1,2 poor illness prognosis,3,4 and poor quality of life.5,6 Meta-analyses have reported significant deficits in executive function, memory and attention in people with MDD currently experiencing a depressive episode, with effect sizes ranging from d = -0.32 to - 0.97.7,8 In BD, a meta-analysis has reported moderate effect size deficits in executive function in people experiencing depressive episodes (d = -0.55) and large effect sizes in people experiencing manic episodes (d = -0.72)9. However, cognitive impairment is not confined to mood episodes, but persists during euthymia in MDD and BD. For example, Rock et al.7 found moderate effect size deficits in executive function and attention in people with remitted MDD, while Semkovska et al.10 identified deficits in working memory and long-term memory. In BD, medium to large effect size deficits in executive function, verbal memory, sustained attention and psychomotor speed have been identified by a meta-analysis.11 Nevertheless, there is considerable heterogeneity in cognitive impairments across people with mood disorders and approximately 35% of people with MDD12 and 20-40% of people with BD13,14 experience moderate to severe impairment in several cognitive domains.

The aetiology of cognitive impairment in mood disorders is not fully understood,15 and determining how cognitive impairment is mediated in MDD and BD is a key priority. Sleep disturbance may be one contributing factor. Sleep disturbances are core features of manic episodes, hypomanic episodes and major depressive episodes manifesting as insomnia or hypersomnia and fatigue in major depressive episodes and a decreased need for sleep in manic or hypomanic episodes.16 There is also growing evidence to suggest that sleep disturbance persists during euthymia in a substantial proportion of people with mood disorders. Clinically significant sleep disturbances are reported by 70% of euthymic people with BD17 and 44-60% of euthymic people with MDD18–20. Moreover, sleep disturbance is associated with higher rates of relapse and suicide attempts in both BD21 and MDD22. Sleep disturbances escalate just before manic and depressive relapse in BD, and worsen during these episodes.23

There is strong evidence detailing the negative effects of sleep disturbance on many aspects of cognition in healthy individuals24, including fragmented memory loss25 and impaired suppression of unwanted thoughts26. Recently, evidence has emerged to suggest an association between sleep disturbance and cognitive impairment in mood disorders. For example, Bradley et al.27 found that people with BD and abnormal sleep patterns, as measured by sleep actigraphy, performed significantly poorer than healthy participants in cognitive performance, whereas people with BD and normal sleep patterns did not significantly differ from healthy participants. As yet, there has not been a systematic review of the relationship between sleep disturbance and cognitive impairment in mood disorders.

The aim of this systematic review was to critically analyse the relationship between sleep disturbance and cognitive impairment in MDD and BD. In particular, the association between sleep disturbance and cognitive impairment, and relevant factors moderating, mediating, and confounding the relationship will be examined.

Methods

Literature search

Two reviewers (OP and NUM) independently performed the literature search. Relevant studies were identified using electronic database searches of PsychINFO, MEDLINE, Embase and Web of Science. The following search string was used: [(sleep disturb*) OR (sleep disorder*) OR (insomn*) OR (hypersomn*)] AND [(cognitive impair*)] AND [(bipolar*) OR (depress*)]. Papers were extracted from inception until February 2021. Only studies written in English were considered. The relevance of the article was initially verified by title and abstract review and then by a further review of each manuscript to verify whether they met the inclusion and exclusion criteria. This systematic review followed PRISMA 202028 guidelines, although a study protocol was not registered.

Inclusion and exclusion criteria

All databases were screened following the same protocol. Included studies were required to include participants with a diagnosis of MDD, BD-I or BD-II, meeting criteria for ICD-929 or subsequent editions, or DSM-III30 or subsequent editions. Included studies were required to measure both sleep disturbance and cognition. Studies were excluded if they: did not primarily include people with a diagnosis of MDD, BD-I or BD-II; included only participants with dysthymia or cyclothymia or with comorbid neurological disorders (e.g. dementia, epilepsy or stroke) or mild cognitive impairment (MCI); included primarily older participants; were follow-up studies or case reports; were not published by a peer-reviewed scientific journal.

Data extraction

The following data were extracted: study name and year; participant sample size, age range, disorder and mood state of participants, measures of sleep and cognition, a summary of main findings and study limitations.

Quality assessment

Two reviewers (OP and NUM) independently assessed the quality of included studies using the Quality Assessment Tool for Quantitative Studies, developed by the Effective Public Health Practice Project (EPHPP).31 The following criteria of each study were rated as either strong, moderate or weak: selection bias, design, confounders, blinding, data collection methods, and withdrawals/drop-outs (if applicable). These ratings were aggregated to form a global rating: studies were rated globally as strong if they received no weak ratings; moderate if they received one weak rating; and weak if they received two or more weak ratings.

Results

A total of 3094 studies were identified, which was reduced to 2208 after duplicates were removed. Following primary assessment of titles and abstracts, this was reduced to 30 studies. Based on secondary assessment of full texts, we included 14 studies that fulfilled the eligibility criteria (please see Figure 1 for further details).

Figure 1.
Figure 1.

PRISMA 2020 Flow Diagram of study selection process

Studies

Of the 14 included studies, eight included people with BD27,32–37, five included people with MDD38–42, and one included both people with MDD and people with BD43 (see Table 1). These studies were published between years 2012-2020. A total of 2353 people with mood disorders were included in these studies, 1083 people with MDD and 1270 people with BD. The mood state of participants varied across studies. Of the eight BD studies, six included only euthymic participants32,33,35,35,37,44, whereas two included participants in any mood state.27,34 Of the five MDD studies, four only included people currently experiencing a depressive episode; however, Wilckens et al. included both people with current depression and people with remitted depression. Mood state was not described in the one study of people with MDD or BD43.

View this table:
Table 1.

Characteristics and findings of studies examining sleep disturbance and cognitive impairment in MDD

BD results

Six of the eight BD studies reported associations between sleep disturbance and cognitive impairment. Kanady et al.33 found that greater sleep time variability predicted poorer working memory (p < 0.01) and verbal learning performance (p < 0.01) in BD. Furthermore, following treatment with cognitive behaviour therapy for insomnia modified for bipolar disorder (CBTI-BD45), a reduction in total wake time predicted improved working memory (p < 0.05) and a reduction in sleep time variability predicted improved verbal learning (p < 0.05). Laskemoen et al.34 found significant associations between insomnia and processing speed (p < 0.001), insomnia and inhibition (p < 0.01), hypersomnia and processing speed (p < 0.01), and hypersomnia and inhibition (p < 0.05) in people with BD, whereas no association between sleep disturbances and cognition was found in healthy participants. Samalin35 et al. found that sleep disturbances were indirectly associated with cognitive function potentially mediated via residual depressive symptoms and perceived cognitive performance (p = 0.001). Another study by Samalin et al.46 reported that participants with impaired cognitive functioning had significantly higher scores (p<0.02), and thus more severe sleep disruptions, on PSQI than participants with satisfactory cognitive functioning. Volkert et al.37 reported that people with BD experiencing persistent sleep disturbances show more severe cognitive dysfunctions (p < 0.05). Bradley et al.27 found that people with BD with normal sleep patterns were not significantly different to healthy participants in cognitive functions, but people with BD and sleep disturbance (including objective measures) performed significantly worse in cognitive tests than healthy participants (p < 0.001). Russo et al.44 found that sleep disturbance was significantly negatively associated with social cognition (r = − 0.273, p = 0.004), but only associated at a trend level with working memory (r = − 0.179, p = 0.061) and visual learning (r = − 0.161, p = 0.094). Boland et al.32 reported no significant associations between sleep disturbance (including objective measures) and cognition, except for a significant negative correlation between daytime dysfunction due to sleep disturbance and working memory (r = − 0.57, p = 0.03).

MDD results

In MDD, Cabanel et al.38 reported that patients with severely impaired sleep quality (PSQI > 10) had significantly poorer performance on the TMT-A (visuomotor processing speed; p = 0.011) and the TMT-B (executive function; p = 0.015) than people with MDD with normal or moderately impaired sleep quality (PSQI < 10). Cha et al.41 found that sleep quality predicted impairments in subjective cognitive performance (p < 0.001) and objective cognitive impairments (p = 0.017). Depression severity was a partial mediator of the relationship between subjective cognitive function and sleep quality (B = -0.43; 95% CI, -0.56, -0.33; B = -0.18; 95% CI, -0.30, -0.07 after controlling for depression severity). Wilckens et al.42 reported that higher wake after sleep onset (i.e., longer periods of wakefulness occurring after defined sleep onset), and shorter total sleep time, were linearly associated with slower response time across single-task (p = 0.10) and switching blocks (p = 0.005) considered a proxy for condition-independent psychomotor slowing47; however, these associations were also observed in healthy controls and therefore not specific to MDD. Müller et al.39 found that 25-40% of participants with MDD reported ‘almost always’ daytime sleepiness, non-restorative sleep, attention deficits or memory complaints, with significant correlations between these variables (p < 0.05), as well as curvilinear associations between sleep duration and sleep quality (quadratic contrast, p < 0.05). However, Peng et al.40 reported no significant association between cognition and sleep disturbance (r = 0.029, p = 0.219) in adolescents with first episode MDD.

Results in mixed MDD & BD groups

Soehner and Harvey43 (N = 639 MDD participants; N = 138 BD participants) reported that participants with a mood disorder and insomnia in the past year experienced significantly greater cognitive impairment in the past 30 days than participants with a mood disorder and no insomnia symptoms in the past year (p = 0.004).

Methodological quality assessment

Methodological quality assessment of studies using the EPHPP Quality Assessment Tool for Quantitative Studies31 are displayed in Supplementary Table 1. Selection bias was generally rated as moderate because in most studies participants were sampled from either outpatient clinics or inpatient settings. Study design was generally rated as weak because most were cross-sectional. Most studies controlled for at least 80% of relevant confounding variables, such as age, coffee consumption etc. Blinding was rated as moderate if it was not described, as was the case in almost all studies. Most studies used validated and reliable measures for sleep disturbance (e.g. Pittsburgh Sleep Quality Index, PSQI48) and cognition (e.g. MATRICS Consensus Cognitive Battery, MCCB49), and were therefore rated strong. Where applicable, withdrawals were reported satisfactorily by most studies. There was no association between global rating and positivity of findings.

Discussion

The purpose of this systematic review was to critically analyse the published literature on the relationship between sleep disturbance and cognitive impairment in BD and MDD. Fourteen studies were included in this review, for which quality assessment ranged from weak to strong.

Kanady et al.33 was the only RCT included in this review. This study, in which CBTI-BD45 was administered to participants with BD, found that a reduction in total wake time predicted improved working memory. The study also found that a reduction in sleep time variability predicted improved verbal learning. These findings suggest that sleep disturbance may contribute to cognitive impairment in BD, and that CBTI-BD may be an effective treatment. The remaining studies included in our review used either a longitudinal or cross-sectional design, and therefore did not allow for causal inferences to be made.

Ten of the twelve studies that measured sleep disturbance using subjective measures in participants with either MDD or BD found a significant association between sleep disturbance and cognitive impairment when adjusting for demographic and clinical covariates. In contrast, no significant association was reported in healthy participants, which suggests that this relationship may be specific to mood disorders. Given the strong evidence on the effect of objective sleep disturbance on cognitive impairment in healthy individuals24, this may indicate that subjective experience of sleep impairment may also increase risks for cognitive impairment in people with mood disorders. Some studies also found a curvilinear association, indicating that both extremely low (<5 hours) and extremely high (>11 hours) self-reported sleep durations were associated with cognitive impairment; this was observed in participants with MDD (e.g. Mu□ller et al.39) and in BD (e.g. Laskemoen et al.34). However, there was also evidence to suggest that insomnia may have more deleterious effects on cognitive impairment than hypersomnia. For example, Laskemoen et al.34 found a larger effect size between insomnia and processing speed (F = 15.43, p < 0.001, η2 = 0.019) than hypersomnia (F = 6.87, p < 0.01, η2 = 0.009) in people with BD.

The main disadvantage of using subjective measures to assess sleep disturbance in people with mood disorders is that there is a considerable risk of bias. Euthymic people with either BD or MDD tend to significantly underestimate sleep duration and quality.17,50 Indeed, Boland et al.32 found that people with BD had significantly higher insomnia severity index (ISI) scores than healthy participants (indicating worse sleep quality), yet found no significant difference between BD and healthy participants in objective sleep parameters, as measured by actigraphy. This effect may be due to maladaptive sleep-related beliefs developed during mood episodes, in which sleep disturbance is particularly severe, which are then carried over into euthymia.50 Nevertheless, subjective measures provide valuable information about the perception of sleep disturbance and sleep-related cognitions, and interventions of maladaptive sleep beliefs may be a useful way of treating sleep disturbance in mood disorders51. Although antidepressant treatment produces no change in maladaptive sleep beliefs in MDD50, Cognitive Behavioural Treatment for Insomnia (CBT-I) has been shown to significantly improve maladaptive sleep beliefs in people with insomnia. CBT-I has been found to significantly improve both subjective sleep measures, measured by sleep diaries, and objective sleep measures, measured by polysomnography (PSG).51 Therefore, sleep-related cognitions may be an important target for treating sleep disturbance and potentially cognitive impairment in people with mood disorders.

Only three studies included in this review measured sleep disturbance using objective measures: two examined sleep disturbance in participants with BD using actigraphy27,32 and one investigated sleep disturbance in participants with MDD using polysomnography42. The MDD study that used polysomnography found that longer periods of wakefulness occurring after defined sleep onset were associated with psychomotor slowing, however these associations were not specific to MDD42. One advantage of polysomnography is that it is more accurate than actigraphy in recognising sleep and wake times, and is therefore the ‘gold standard’ of objective sleep measurement. Another key advantage of polysomnography is the ability to measure sleep architecture, however, the Wilckens et al MDD study did not report sleep architecture measurements.

Mood disorders are associated with several sleep architecture abnormalities, particularly altered distribution of rapid eye movement (REM) sleep in MDD52 and BD53. Components of sleep architecture have been linked to aspects of cognitive impairment in healthy individuals. For example, time in slow wave sleep contributes to processing speed in healthy individuals.54 Abnormal sleep architecture may be associated with cognitive impairment in mood disorders, so sleep architecture may be a highly relevant variable to measure. Moreover, knowledge of the specific components of sleep archiecture associated with improvements in mental health or cognition could be targeted in interventions for treatment or prevention. For example, enhancing slow oscillation activity via non-invasive auditory stimulation has been shown to improve memory in healthy individuals55. Thus, we suggest that future studies of the role of sleep in cognition in mood disorders use polysomnography where possible.

Interestingly, the two BD studies which used actigraphy had opposite findings. Bradley et al.27 found a significant association between objective sleep disturbance and cognitive impairment in participants with BD (p < 0.001). Specifically, participants with BD and abnormal sleep patterns were found to experience deficits in attention and executive function but normal verbal memory. In contrast, Boland et al.32 found no significant association between objective sleep disturbance and cognitive impairment in participants with BD. However, this study included a relatively small sample size of participants with BD (n=24) which implies low statistical power and risk of type-II error. Nevertheless, taken together, these two BD studies are inconclusive as to the association between objective sleep disturbance and cognitive impairment in people with BD and highlights the need for future research using larger sample sizes and PSG.

Limitations

This review reflects the limited number of studies in the field and so the relatively small number of participants in which the associations between sleep disturbance and cognitive impairment have been investigated, particularly regarding MDD, limits our power to draw wider conclusions. The studies included in our review generally had small sample sizes (N = 48 - 4555), which limited statistical power and increased risks of type-II error. A meta-analysis was not performed because there was significant heterogeneity between studies in the age and mood state of participants, as well as the measures of sleep and cognition used.

In studies examining sleep disturbance and cognitive impairment in mood disorders, it is normally best practice to include only euthymic participants because mood state may affect both sleep disturbance and cognitive impairment, and therefore may be a confound.56 The MDD studies were particularly weak in this regard, as four of the five MDD studies only included people currently experiencing a depressive episode. The BD studies were stronger, but still varied: six studies only included participants that were euthymic,32,33,35,37,44,46 and two included participants in any mood state.27,34

With the exception of Wilckens et al.42, none of the included studies adjusted for the use of psychotropic medications in the relationship between sleep disturbance and cognitive impairment. Psychotropic medication may be a confounding variable, as they can affect both sleep and cognition in people with mood disorders.57 Indeed, Volkert et al.37 reported that antipsychotic treatment and polypharmacy were related to cognitive impairment. Furthermore, many antipsychotics affect REM sleep, which has been linked to emotional memory processing58. Without adjusting for the use of psychotropic medications, it is unclear which medications alter the relationship between sleep disturbance and cognitive impairment in mood disorders, and to what extent.

Suggestions for future research

Theoretically, sleep disturbance may cause, predispose or exacerbate cognitive impairment in mood disorders but this link has yet to be adequately evaluated. Further research is clearly needed in this area in participants with mood disorders. Based on the evaluation of current evidence, we would suggest that future studies follow five recommendations. First, studies should include only euthymic participants, to remove the confounding effect of mood state. Second, they should use objective measures of sleep, ideally polysomnography, to evaluate the role of sleep disturbance in mediating cognitive impairment, and to determine which aspects of sleep architecture are linked to cognition in these individuals. Third, all studies should use a comprehensive cognitive battery such as the BACS-A59 or ideally the ISBD-BANC60. Fourth, analyses should adjust for the use of psychotropic medications, as these may also have a confounding effect. Finally, we would suggest that studies use a prospective longitudinal design, and, if possible, use a randomised clinical trial design for intervention studies.

Conclusion

In conclusion, our systematic review provides preliminary evidence for an association between sleep disturbance and cognitive impairment in mood disorders. The studies identified by this systematic review found increased rates of both subjective sleep disturbances and cognitive impairment in people with MDD and BD, compared to healthy participants. Ten of the twelve studies that measured sleep disturbance using subjective measures of sleep found a significant association between sleep disturbance and cognitive impairment across both diagnoses when adjusting for demographic and clinical covariates, whereas no significant association was found in healthy participants. In contrast, the evidence was scarcer and more conflicting with regards to whether objectively measured sleep abnormalities are associated with cognitive impairment in people with mood disorders: two out of three studies reported significant associations. Only one study33 conducted an intervention, and reported that improved sleep predicted an improvement in cognition in BD. As cognitive impairment has significant implications for psychosocial functioning in people with mood disorders, these findings highlight the importance of effectively identifying and treating sleep disturbances in people with MDD and BD.

Data Availability

No data was used.

Contributors

OP wrote the report with input from NUM, KWM, SAC, IR, AHY and PRAS. OP and NUM independently performed the literature search and quality assessment. All authors had full access to all the papers in the study and had final responsibility for the decision to submit for publication.

Declaration of interests

OP, NUM, SAC and IR declare no competing interests.

KWM has received consultancy fees from Lundbeck and Janssen-Cilag in the past three years.

PRAS reports non-financial support from Janssen Research and Development LLC, personal fees and non-financial support from Frontiers in Psychiatry, personal fees from Allergan, a grant from H Lundbeck, grants and non-financial support from Corcept Therapeutics, outside the submitted work.

AHY declares:

Employed by King’s College London; Honorary Consultant SLaM (NHS UK)

Deputy Editor, BJPsych Open

Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders:

Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS

Consultant to Johnson & Johnson

Consultant to Livanova

Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova.

Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.”

Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”

Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”

UK Chief Investigator for Novartis MDD study MIJ821A12201

Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)

No shareholdings in pharmaceutical companies

Supplementary Tables

View this table:
Supplementary Table 1:

Methodological evaluation of studies using the EPHPP Quality Assessment Tool for Quantitative Studies

References

  1. 1.↵
    McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527. doi:10.1002/da.22063
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    O’Donnell LA, Deldin PJ, Grogan-Kaylor A, et al. Depression and executive functioning deficits predict poor occupational functioning in a large longitudinal sample with bipolar disorder. J Affect Disord. 2017;215:135–142. doi:10.1016/j.jad.2017.03.015
    OpenUrlCrossRef
  3. 3.↵
    Martino DJ, Igoa A, Scápola M, Marengo E, Samamé C, Strejilevich SA. Functional Outcome in the Middle Course of Bipolar Disorder: A Longitudinal Study. J Nerv Ment Dis. 2017;205(3):203—206. doi:10.1097/nmd.0000000000000583
    OpenUrlCrossRef
  4. 4.↵
    Zhang B-H, Feng L, Feng Y, et al. The Effect of Cognitive Impairment on the Prognosis of Major Depressive Disorder. J Nerv Ment Dis. 2020;208(9). https://journals.lww.com/jonmd/Fulltext/2020/09000/The_Effect_of_Cognitive_Impairment_on_the.8.aspx
  5. 5.↵
    Depp CA, Mausbach BT, Harmell AL, et al. Meta□analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14(3):217–226.
    OpenUrlCrossRef
  6. 6.↵
    Cambridge OR, Knight MJ, Mills N, Baune BT. The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: A systematic review. Psychiatry Res. 2018;269:157–171. doi:10.1016/j.psychres.2018.08.033
    OpenUrlCrossRef
  7. 7.↵
    Rock P, Roiser J, Riedel W, Blackwell A. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review. Psychol Bull. 2013;139(1):81–132. doi:10.1037/a0028727
    OpenUrlCrossRefPubMed
  9. 9.↵
    Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: Profile and effects of clinical state. Neuropsychology. 2009;23(5):551–562. doi:10.1037/a0016277
    OpenUrlCrossRefPubMed
  10. 10.↵
    Semkovska M, Quinlivan L, O’Grady T, et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):851–861. doi:10.1016/S2215-0366(19)30291-3
    OpenUrlCrossRef
  11. 11.↵
    Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1-2):1–20. doi:10.1016/j.jad.2008.06.009
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Pu S, Noda T, Setoyama S, Nakagome K. Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications. Psychol Med. 2018;48(16):2717–2729. doi:10.1017/S003329171800034X
    OpenUrlCrossRef
  13. 13.↵
    Burdick KE, Russo M, Frangou S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083–3096. doi:10.1017/S0033291714000439
    OpenUrlCrossRef
  14. 14.↵
    Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. J Affect Disord. 2016;205:378–386.
    OpenUrl
  15. 15.↵
    Depp CA, Dev S, Eyler LT. Bipolar Depression and Cognitive Impairment. Psychiatr Clin North Am. 2016;39(1):95–109. doi:10.1016/j.psc.2015.09.004
    OpenUrlCrossRef
  16. 16.↵
    American Psychiatric Association, American Psychiatric Association, eds. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American Psychiatric Association; 2013.
  17. 17.↵
    Harvey AG, Schmidt DA, Scarnà A, Semler CN, Goodwin GM. Sleep-Related Functioning in Euthymic Patients With Bipolar Disorder, Patients With Insomnia, and Subjects Without Sleep Problems. Am J Psychiatry. 2005;162(1):50–57. doi:10.1176/appi.ajp.162.1.50
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety. 2011;28(2):137–144.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.
    Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221–225.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Carney CE, Segal ZV, Edinger JD, Krystal AD. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. Published online 2007.
  21. 21.↵
    Sylvia LG, Dupuy JM, Ostacher MJ, et al. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol (Oxf). 2012;26(8):1108–1112. doi:10.1177/0269881111421973
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    Li SX, Lam SP, Chan JWY, Yu MWM, Wing Y-K. Residual Sleep Disturbances in Patients Remitted From Major Depressive Disorder: A 4-Year Naturalistic Follow-up Study. Sleep. 2012;35(8):1153–1161. doi:10.5665/sleep.2008
    OpenUrlCrossRef
  23. 23.↵
    Jackson A, Cavanagh J, Scott J. A systematic review of manic and depressive prodromes. J Affect Disord. 2003;74(3):209–217.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Krause AJ, Simon EB, Mander BA, et al. The sleep-deprived human brain. Nat Rev Neurosci. 2017;18(7):404–418. doi:10.1038/nrn.2017.55
    OpenUrlCrossRefPubMed
  25. 25.↵
    Ashton JE, Harrington MO, Langthorne D, Ngo H-VV, Cairney SA. Sleep deprivation induces fragmented memory loss. Learn Mem. 2020;27(4):130–135.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Harrington MO, Ashton JE, Sankarasubramanian S, Anderson MC, Cairney SA. Losing Control: Sleep Deprivation Impairs the Suppression of Unwanted Thoughts. Published online 2021:17.
  27. 27.↵
    Bradley AJ, Anderson KN, Gallagher P, McAllister-Williams RH. The association between sleep and cognitive abnormalities in bipolar disorder. Psychol Med. 2020;50(1):125–132. doi:10.1017/S0033291718004038
    OpenUrlCrossRef
  28. 28.↵
    Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Published online March 29, 2021:n71. doi:10.1136/bmj.n71
    OpenUrlFREE Full Text
  29. 29.↵
    World Health Organization. International Classification of Diseases—Ninth Revision (ICD-9). Wkly Epidemiol Rec. 1988;63(45):343–344.
    OpenUrl
  30. 30.↵
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd Ed.).; 1980.
  31. 31.↵
    Thomas H, Ciliska D, Dobbins M. Quality assessment tool for quantitative studies. Tor Eff Public Health Pract Proj McMaster Univ. Published online 2003.
  32. 32.↵
    Boland EM, Stange JP, Molz Adams A, et al. Associations between sleep disturbance, cognitive functioning and work disability in Bipolar Disorder. Psychiatry Res. 2015;230(2):567–574. doi:10.1016/j.psychres.2015.09.051
    OpenUrlCrossRef
  33. 33.↵
    Kanady JC, Soehner AM, Klein AB, Harvey AG. The association between insomnia-related sleep disruptions and cognitive dysfunction during the inter-episode phase of bipolar disorder. J Psychiatr Res. 2017;88:80–88. doi:10.1016/j.jpsychires.2017.01.001
    OpenUrlCrossRef
  34. 34.↵
    Laskemoen JF, Büchmann C, Barrett EA, et al. Do sleep disturbances contribute to cognitive impairments in schizophrenia spectrum and bipolar disorders? Eur Arch Psychiatry Clin Neurosci. Published online October 5, 2019. doi:10.1007/s00406-019-01075-0
    OpenUrlCrossRef
  35. 35.↵
    Samalin L, Boyer L, Murru A, et al. Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. J Affect Disord. 2017;210:280–286. doi:10.1016/j.jad.2016.12.054
    OpenUrlCrossRef
  36. 36.
    Ullah MH. Effects of sleep disturbance on cognitive functioning in bipolar disorder type 1: a correlational study design. ProQuest Diss Publ. Published online 2017.
  37. 37.↵
    Volkert J, Kopf J, Kazmaier J, et al. Evidence for cognitive subgroups in bipolar disorder and the influence of subclinical depression and sleep disturbances. Eur Neuropsychopharmacol. 2015;25(2):192–202. doi:10.1016/j.euroneuro.2014.07.017
    OpenUrlCrossRef
  38. 38.↵
    Cabanel N, Schmidt A-M, Fockenberg S, et al. Evening preference and poor sleep independently affect attentional-executive functions in patients with depression. Psychiatry Res. 2019;281:112533. doi:10.1016/j.psychres.2019.112533
    OpenUrlCrossRef
  39. 39.↵
    Müller MJ, Olschinski C, Kundermann B, Cabanel N. Sleep duration of inpatients with a depressive disorder: associations with age, subjective sleep quality, and cognitive complaints. Arch Psychiatr Nurs. 2017;31(1):77–82. doi:10.1016/j.apnu.2016.08.008
    OpenUrlCrossRef
  40. 40.↵
    Peng S, Li J, Wu Z, et al. Characteristics of and factors influencing cognitive impairment in adolescent patients with first-episode depression. Vulnerable Child Youth Stud. 2018;13(4):317–324. doi:10.1080/17450128.2018.1515517
    OpenUrlCrossRef
  41. 41.↵
    Cha DS, Carmona N, Cha RH, et al. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. Ann Clin PSYCHIATRY. Published online 2019:10.
  42. 42.↵
    Wilckens KA, Kline CE, Bowman MA, et al. Does objectively-assessed sleep moderate the association between history of major depressive disorder and task-switching? J Affect Disord. 2020;265:216–223. doi:10.1016/j.jad.2020.01.003
    OpenUrlCrossRef
  43. 43.↵
    Soehner AM, Harvey AG. Prevalence and Functional Consequences of Severe Insomnia Symptoms in Mood and Anxiety Disorders: Results from a Nationally Representative Sample. Sleep. 2012;35(10):1367–1375. doi:10.5665/sleep.2116
    OpenUrlCrossRefPubMed
  44. 44.↵
    Russo M, Mahon K, Shanahan M, et al. The relationship between sleep quality and neurocognition in bipolar disorder. J Affect Disord. 2015;187:156–162. doi:10.1016/j.jad.2015.08.009
    OpenUrlCrossRef
  45. 45.↵
    Harvey AG, Soehner AM, Kaplan KA, et al. Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: A pilot randomized controlled trial. J Consult Clin Psychol. 2015;83(3):564–577. doi:10.1037/a0038655
    OpenUrlCrossRefPubMed
  46. 46.↵
    Samalin L, de Chazeron I, Vieta E, Bellivier F, Llorca P-M. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016;18(2):164–173. doi:10.1111/bdi.12376
    OpenUrlCrossRef
  47. 47.↵
    White DA, Myerson J, Hale S. How cognitive is psychomotor slowing in depression? evidence from a meta-analysis. Aging Neuropsychol Cogn. 1997;4(3):166–174. doi:10.1080/13825589708256645
    OpenUrlCrossRef
  48. 48.↵
    Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    Wysokinski A, Dzienniak M, Kloszewska I. Assessment of cognitive performance using CNS vital signs after electroconvulsive treatment of schizophrenia. J ECT. 2014;30(1):e5–e6.
    OpenUrl
  50. 50.↵
    Carney CE, Harris AL, Friedman J, Segal ZV. Residual sleep beliefs and sleep disturbance following cognitive behavioral therapy for major depression. Depress Anxiety. 2011;28(6):464–470.
    OpenUrlPubMed
  51. 51.↵
    Morin C, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther. 2002;40(7):741–752.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Hutka P, Krivosova M, Muchova Z, et al. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. Int J Mol Sci. 2021;22(3):1333. doi:10.3390/ijms22031333
    OpenUrlCrossRef
  53. 53.↵
    Eidelman P, Talbot LS, Gruber J, Hairston I, Harvey AG. Sleep architecture as correlate and predictor of symptoms and impairment in inter-episode bipolar disorder: taking on the challenge of medication effects: Sleep and inter-episode bipolar disorder. J Sleep Res. 2010;19(4):516–524. doi:10.1111/j.1365-2869.2010.00826.x
    OpenUrlCrossRefPubMed
  54. 54.↵
    della Monica C, Johnsen S, Atzori G, Groeger JA, Dijk D-J. Rapid Eye Movement Sleep, Sleep Continuity and Slow Wave Sleep as Predictors of Cognition, Mood, and Subjective Sleep Quality in Healthy Men and Women, Aged 20–84 Years. Front Psychiatry. 2018;9:255. doi:10.3389/fpsyt.2018.00255
    OpenUrlCrossRef
  55. 55.↵
    Ngo H-VV, Martinetz T, Born J, Mölle M. Auditory closed-loop stimulation of the sleep slow oscillation enhances memory. Neuron. 2013;78(3):545–553.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    Miskowiak K, Burdick K, Martinez-Aran A, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord. 2018;20(3):184–194. doi:10.1111/bdi.12595
    OpenUrlCrossRef
  57. 57.↵
    Staner L. Sleep disturbances, psychiatric disorders, and psychotropic drugs. Dialogues Clin Neurosci. 2005;7(4):323.
    OpenUrlPubMed
  58. 58.↵
    Walker MP, van Der Helm E. Overnight therapy? The role of sleep in emotional brain processing. Psychol Bull. 2009;135(5):731.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-297.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Yatham LN, Torres IJ, Malhi GS, et al. The international society for bipolar disorders– battery for assessment of neurocognition (ISBD□BANC). Bipolar Disord. 2010;12(4):351–363.
    OpenUrlCrossRef
  61. 61.
    Fietze I, Wiesenacker D, Blau A, Penzel T. Sleep quality in a hospital and effects of noise. Somnologie-Schlafforschung Schlafmed. 2008;12(2):167.
    OpenUrl
  62. 62.
    Wechsler D. Wechsler Test of Adult Reading: WTAR: Psychological Corporation. San Antonio Tx. Published online 2001.
  63. 63.
    Wechsler D. Wechsler Memory Scale (WMS-III). Vol 14. Psychological corporation San Antonio, TX; 1997.
  64. 64.
    Morin CM. Insomnia: Psychological Assessment and Management. Guilford press; 1993.
  65. 65.
    Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–486.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.
    Endicott J, Spitzer R. Schedule for affective disorders and schizophrenia (SADS). Acta Psychiatr Belg. 1987;87(4):361–516.
    OpenUrlPubMed
  67. 67.
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
    OpenUrlAbstract/FREE Full Text
  68. 68.
    Kaufman AS. Manual for the Kaufman brief intelligence test. Circ Pines MN Am Guid Serv. Published online 1990.
  69. 69.
    Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. J Int Neuropsychol Soc JINS. 2004;10(2):301.
    OpenUrl
  70. 70.
    Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci. 1982;298(1089):199–209.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.
    Niemann H, Sturm W, Thöne-Otto A, Wilmes K. California verbal learning test, version 21. Mödling Schuhfried GmbH. Published online 2011.
  72. 72.
    Woods SP, Delis DC, Scott JC, Kramer JH, Holdnack JA. The California Verbal Learning Test–second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol. 2006;21(5):413–420.
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.
    Nelson HE. National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual. Nfer-Nelson; 1982.
  74. 74.
    Dinges DF, Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Methods Instrum Comput. 1985;17(6):652–655.
    OpenUrlCrossRefWeb of Science
  75. 75.
    Fan J, McCandliss BD, Sommer T, Raz A, Posner MI. Testing the efficiency and independence of attentional networks. J Cogn Neurosci. 2002;14(3):340–347.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.
    Pariante CM, Alhaj HA, Arulnathan VE, et al. Central glucocorticoid receptor-mediated effects of the antidepressant, citalopram, in humans: a study using EEG and cognitive testing. Psychoneuroendocrinology. 2012;37(5):618–628.
    OpenUrlCrossRefPubMed
  77. 77.
    Samalin L, Llorca PM, Giordana B, et al. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). J Affect Disord. 2014;159:94–102.
    OpenUrl
  78. 78.
    Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3(1):5.
    OpenUrlCrossRefPubMed
  79. 79.
    Glahn DC, Almasy L, Barguil M, et al. Neurocognitive endophenotypes for bipolar disorder identified in multiplex multigenerational families. Arch Gen Psychiatry. 2010;67(2):168–177.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.
    Zimmermann P, Fimm B. A test battery for attentional performance. Appl Neuropsychol Atten Theory Diagn Rehabil. 2002;110:151.
    OpenUrl
  81. 81.
    Aschenbrenner S, Tucha O, Lange K. Manual zum RWT (Regensburger Wortflüssigkeits-Test; Handanweisung). Published online 2000.
  82. 82.
    Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. sleep. 1991;14(6):540–545.
    OpenUrlCrossRefPubMedWeb of Science
Back to top
Posted August 13, 2021.
Download PDF
Data/Code
Email
The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review
Oliver Pearson, Nora Uglik-Marucha, Kamilla W. Miskowiak, Scott A. Cairney, Ivana Rosenzweig, Allan H. Young, Paul R.A. Stokes
medRxiv 2021.08.12.21261470; doi: https://doi.org/10.1101/2021.08.12.21261470
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area